RSS   Newsletter   Contact   Advertise with us
Post Online Media

Sygnis appoints Heikki Lanckriet as co-CEO and CSO

SygnisSygnis AG, a pharmaceutical company, announced the appointment of Heikki Lanckriet as co-CEO and chief scientific officer.
Article continues below

READ MORE Hill & Smith Holdings appoints Mark Reckitt as director

The CSO role is a newly created position at SYGNIS. Dr. Lanckriet currently is chief executive officer of Expedeon Holdings Ltd.

Dr. Lanckriet will also become a member of the Management Board of SYGNIS, along with Pilar de la Huerta, who will serve as co-CEO and Chief Financial Officer of the combined organization.

Dr. Lanckriet has co-founded Expedeon in 2003. At Expedeon, he has served as Chief Operating Officer, CSO and CEO, his current position, accumulating a deep knowledge of the life sciences tools and reagents business.

Dr. Lanckriet holds a bachelor’s and master’s degree in biochemical engineering from the University of Ghent, Belgium and a PhD in biochemical engineering from the University of Cambridge, UK.

He has published papers in peer-reviewed international scientific journals and is named inventor on a number of patents.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy